GNCA stock hits $0.0001 pre-market Jan 06, 2026: assess downside and catalysts
GNCA stock opened pre-market at $0.0001 on Jan 06, 2026 after a steep intraday fall from the prior close of $0.0039. Volume was modest at 30,268 shares versus a 50-day average of 80,568, signaling thin liquidity on the NASDAQ in the United States. Investors should note the stock’s wide 52-week range, with a year high of $1.45 and year low of $0.0001, and the company’s Chapter 11 history when weighing any short-term rebounds. This piece breaks down valuation metrics, recent trading drivers, and a concise outlook for GNCA stock.
GNCA stock price action and market snapshot
Genocea Biosciences, Inc. (GNCA) opened pre-market at $0.0001 after a change of -97.44% versus the previous close of $0.0039. The stock’s day range was $0.0001–$0.0001 and reported volume was 30,268 shares, below the average volume of 80,568, highlighting low liquidity on NASDAQ in the United States. Price averages show a 50-day average of $0.00472 and a 200-day average of $0.11462, underlining the ongoing downtrend.
Fundamentals and GNCA stock valuation metrics
Latest company metrics show revenue per share TTM of $0.02 and net income per share TTM of -$0.22, reflecting a biotech still reporting losses. Book value per share is $0.39 and cash per share is $0.54, with a current ratio of 2.24, indicating short-term liquidity. Price multiples are not meaningful given the near-zero market capitalization and the stock’s historical volatility; price/book sits effectively near 0.00 because market cap is reported as 0.
Clinical pipeline, corporate events and GNCA news linkages
Genocea’s pipeline historically included GEN-009 and GEN-011 programs and the ATLAS discovery platform; the company filed Chapter 11 in July 2022. Ongoing clinical or restructuring updates will be the primary drivers of GNCA stock moves given limited trading liquidity. For the latest news and filings related to GNCA, see MarketBeat coverage and company filings for real-time updates MarketBeat GNCA page and broader MarketBeat news MarketBeat News.
Technical and trading risks for GNCA stock
The technical picture is distorted by extremely low price and volume; the effective spread can be wide and limit orders may not fill. Average daily volume of 80,568 leaves a relative volume of 0.38, so single trades can move the price materially. Year-to-date and multi-year percentage changes show declines exceeding 99.00%, indicating severe long-term downside and high volatility.
Meyka AI grade and analyst framing for GNCA stock
Meyka AI rates GNCA with a score of 62.75 out of 100 (B, HOLD). This grade factors in S&P 500 benchmark comparison, sector and industry comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. The grade highlights limited positive signals from cash per share and working capital but is offset by chronic losses, bankruptcy history, and near-zero market cap. These grades are not guarantees and do not constitute investment advice.
Price targets, forecast and GNCA stock outlook
Meyka AI’s forecast model projects a 12-month reference level of $0.0005 versus the current price of $0.0001, implying an upside of roughly +400.00% if the model scenario occurs. A conservative recovery scenario yields a short-term target of $0.0010 and a downside scenario remains near $0.0000 given the company’s restructuring history. Forecasts are model-based projections and not guarantees; outcomes depend on corporate filings, clinical updates and liquidity.
Final Thoughts
Key takeaways for GNCA stock: the pre-market price of $0.0001 on Jan 06, 2026 reflects extreme illiquidity and legacy restructuring risks. Fundamentals show cash per share of $0.54 and a current ratio of 2.24, which provide limited balance-sheet cushions, but the company reports negative net income per share of -$0.22 and operates in a capital-intensive biotech sector. Meyka AI rates GNCA with a score of 62.75/100 (B, HOLD) and models a 12-month reference of $0.0005, implying theoretical upside of +400.00% from today’s price; investors should treat this as a scenario, not a promise. Trading GNCA on NASDAQ in the United States carries high execution risk, potential delisting or corporate actions, and wide bid-ask spreads. For active traders, watch filings, Chapter 11 developments and any clinical readouts. For most portfolios, GNCA may remain a speculative position that requires rigorous risk controls and position sizing. Meyka AI, an AI-powered market analysis platform, provides this model-based context to help frame GNCA stock risk and opportunity; always cross-check filings and primary sources before trading.
FAQs
GNCA stock’s fall to **$0.0001** reflects thin liquidity, a prior close of **$0.0039**, and lingering restructuring risks from a Chapter 11 filing. Low trading volumes and the biotech’s financial losses contributed to the sharp drop.
Meyka AI’s forecast model projects a 12-month reference of **$0.0005** versus the current **$0.0001**, implying about **+400.00%** upside in the model scenario. Forecasts are projections and not guarantees.
Given GNCA’s Chapter 11 history, very low float price and low liquidity on NASDAQ, most investors should treat GNCA stock as highly speculative and use small position sizes. Conduct due diligence on filings and clinical updates before considering exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
